UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2013
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Maryland
|
001-14494
|
33-0724736
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
10003 Woodloch Forest Drive
The Woodlands, TX
|
77380
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (832) 934-1825
__________________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07 Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders of Pernix Therapeutics Holdings, Inc. (the “Company”) was held on June 19, 2013. At the annual meeting, our stockholders (i) elected each nominee to serve as a Company director until the next annual meeting of stockholders, (ii) ratified the selection of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013, (iii) approved, on an advisory basis, the Company’s executive compensation and (iv) approved, on an advisory basis, the Company’s proposal for the frequency of the advisory vote on executive compensation.
|
Nominee
|
Number of Votes For
|
Number of Votes Withheld
|
||
|
Michael C. Pearce
|
23,712,649
|
53,535
|
||
|
Cooper C. Collins
|
23,705,418
|
60,584
|
||
|
Anthem H. Blanchard
|
26,684,320
|
81,682
|
||
|
Steven A. Elms
|
23,711,945
|
54,057
|
||
|
James E. Smith, Jr.
|
16,057,647
|
7,708,355
|
The final voting tabulation for the ratification of the independent registered public accounting firm was as follows:
|
Proposal
|
Number of Votes For
|
Number of Votes Against
|
Abstentions
|
|||
|
Ratification of Cherry Bekaert LLP
|
29,253,032
|
12,775
|
1,605
|
The final voting tabulation for the approval, on an advisory basis, of the Company’s executive compensation was as follows:
|
Proposal
|
Number of Votes For
|
Number of Votes Against
|
Abstentions
|
|||
|
Approval, on an advisory basis, the Company’s executive compensation
|
23,689,590
|
72,830
|
3,582
|
The final voting tabulation for the approval, on an advisory basis, of the Company’s proposal for a vote on the frequency of the advisory vote on executive compensation was as follows:
|
Proposal
|
One Year
|
Two Years
|
Three Years
|
Abstentions
|
||||
|
Approval, on an advisory basis, of the frequency of the advisory vote on executive comp.
|
14,900,999
|
641
|
8,856,016
|
8,095
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PERNIX THERAPEUTICS HOLDINGS, INC.
|
|||
|
Dated: June 20, 2013
|
By:
|
/s/ Tracy S. Clifford | |
|
Tracy S. Clifford
|
|||
|
Principal Financial Officer and
Principal Accounting Officer
|
|||
3